Background
Researchers have indicated that they want access to novel target antibodies quickly to aid in their research. IMGENEX is pleased to be able to offer researchers access to cutting-edge products that are still in the process of characterization/validation. IMGENEX’s ‘IMX’ antibody line is shown by ELISA to bind to the peptide used as immunogen. Investigators should empirically determine the suitability of the antibody, including optimal dilutions, for other applications of interest.
 |
We cannot guarantee that the yet-to-be-fully validated antibody will work in any application other than in an ELISA against the peptide used as immunogen and therefore cannot offer a refund if the antibody does not work in your application. |
|
The antibody is offered at a lower price compared to a more highly validated antibody. |
|
We are not able to provide the immunogen for the antibodies, but do provide the amino acid sequence. |
These antibodies are not fully validated and we appreciate your feedback. Customer feedback is used to help generate testing methodologies which can lead to further product validation or withdrawal.
JAK2 is a member of the Jak kinase family which is ubiquitously expressed. It associates with cytokine receptors and is essential for signal transduction by mediating tyrosine phosphorylation. The protein is composed of four conserved domains, the NH2-terminal FERM domain which is required for interaction with cytokine receptors, the adjacent SH2-like fold with no known function, and a kinase-like COOH-terminal JH2 domain that is devoid of enzymatic activity but that inhibits the activity of the COOH-terminal JH1 tyrosine kinase domain. Human JAK2 gene is localized in the chromosomal region 9p24. The protein is highly expressed in spleen, peripheral blood leukocytes, testis, heart and skeletal muscle. Recent studies have implicated de-regulation of JAK2 kinase activity by chromosomal translocations in hematopoietic tumors. |
